Results 251 to 260 of about 225,025 (354)

The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024. [PDF]

Hum Vaccin Immunother
Li Y, Xia H, Zhang H, Lu Y, Zhou H, Yu R, Huang P.   +6 more
europepmc   +1 more source

[Influenza vaccine and influenza vaccination].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1993
L, Flugsrud, H, Nøkleby
openaire   +1 more source

Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans

Immunology &Cell Biology, EarlyView.
In this study, we characterize a distinct subpopulation of undifferentiated invariant natural killer T (iNKT) cells in the peripheral blood of healthy adults, which are characterized by CD38 expression in a resting state. This CD38+ subset closely resembles iNKT cells from cord blood and thymus, exhibiting a unique cytokine profile and alterations in ...
Christopher Menne, Naeimeh Tavakolinia, Louis Perriman, Wiebke Moskorz, Christine Cosmovici, Andreas Walker, Lara Olejnik, Katharina Raba, Mei RM Du, Fernando J Rossello, Igor E Konstantinov, Stuart P Berzins, Daniel G Pellicci, Jörg Timm   +13 more
wiley   +1 more source

IAPSM's Position Paper on Influenza Vaccines for Adult Immunization in India. [PDF]

Indian J Community Med
Sharma N, Verma M, Goel K, Kulkarni MM, Bhardwaj A, Sharma S, Singh T, Gupta M, Nadda A, Sankhe LR.   +9 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant

, 2011
Tarek Hamouda, Joyce A. Sutcliffe, Susan Ciotti, James R. Baker   +3 more
openalex   +1 more source

Mass‐Standardised Differential Antibody Binding to a Spectrum of SARS‐CoV‐2 Variant Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4/5, BA.2.75 and BA.2.12.1 Variants—Antibody Immunity Endotypes

Immunology, EarlyView.
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton, Shivali Kohli, Jordan Twynham, Aaron C. Westlake, Alex Antill, Rouslan V. Olkhov, Andrew M. Shaw   +6 more
wiley   +1 more source

Do Pregnant Persons Want Influenza Vaccines? Knowledge, Attitudes, Perceptions, and Practices Toward Influenza Vaccines in 8 Low- and Middle-Income Countries. [PDF]

J Infect Dis
McCarron M, Yau TS, Griffin C, Marcenac P, Ebama MS, Lafond KE, Igboh LS, Duca LM, Bino S, Bettaieb J, Dhaouadi S, Sahakyan G, Cherkaoui I, Alj L, Coulibaly D, Lutwama JJ, Douba A, N'Gattia A, Khanthamaly V, Tengbriacheu C, Patthammavong C, Lambach P, Otorbaeva D, Azziz-Baumgartner E, Bresee JS.   +24 more
europepmc   +1 more source

Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season

Yawen Jiang, Jiatong Sun, Fang Huang, Xu Xie, Xin Wang, Xiaoliang Wu, Min Jiang, Ying Sun, Hui Liu, Huiqiao Gu, Quan Lü, Xiaozhen Chen, Tiejian Feng, Shisong Fang, Jianhua Lu, Yuelong Shu   +15 more
openalex   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source